Korro Bio Showcases RNA Editing Technology at Multiple International Conferences
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy KRRO?
Source: Newsfilter
- Conference Presentations: Korro Bio will present its GalNAc-conjugated oligonucleotide KRRO-121 at the 3rd International Conference on Ureagenesis Defects from April 22-24, 2026, showcasing its robust ammonia clearance in preclinical hyperammonemia models, highlighting its potential in treating rare diseases.
- ASGCT Participation: At the American Society of Gene and Cell Therapy Annual Meeting from May 11-15, 2026, Korro will discuss the effectiveness of its RNA editing oligonucleotide in restoring Alpha-1 Antitrypsin function in AATD models, demonstrating its application prospects in precision medicine.
- Technological Innovations: Korro's OPERA® platform will be featured at the TIDES USA conference from May 11-14, 2026, emphasizing its innovations in large-scale RNA editing that are crucial for generating drug candidates, potentially accelerating the development of new therapies.
- EASL Congress Involvement: At the EASL Congress from May 27-30, 2026, Korro will present research on the increased healthcare resource utilization associated with uncontrolled ammonia in hepatic encephalopathy, further underscoring its contributions to liver disease research.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KRRO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KRRO
Wall Street analysts forecast KRRO stock price to rise
8 Analyst Rating
0 Buy
8 Hold
0 Sell
Hold
Current: 14.390
Low
7.00
Averages
25.75
High
81.00
Current: 14.390
Low
7.00
Averages
25.75
High
81.00
About KRRO
Korro Bio, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Korro Bio Showcases RNA Editing Technology at Multiple International Conferences
- Conference Presentations: Korro Bio will present its GalNAc-conjugated oligonucleotide KRRO-121 at the 3rd International Conference on Ureagenesis Defects from April 22-24, 2026, showcasing its robust ammonia clearance in preclinical hyperammonemia models, highlighting its potential in treating rare diseases.
- ASGCT Participation: At the American Society of Gene and Cell Therapy Annual Meeting from May 11-15, 2026, Korro will discuss the effectiveness of its RNA editing oligonucleotide in restoring Alpha-1 Antitrypsin function in AATD models, demonstrating its application prospects in precision medicine.
- Technological Innovations: Korro's OPERA® platform will be featured at the TIDES USA conference from May 11-14, 2026, emphasizing its innovations in large-scale RNA editing that are crucial for generating drug candidates, potentially accelerating the development of new therapies.
- EASL Congress Involvement: At the EASL Congress from May 27-30, 2026, Korro will present research on the increased healthcare resource utilization associated with uncontrolled ammonia in hepatic encephalopathy, further underscoring its contributions to liver disease research.
See More
"Q1's 5 Major Insider Purchases: Should You Buy, Sell, or Hold in Q2?"
Insider Buying Trends: In Q1 2026, insiders showed strong confidence by purchasing stocks, particularly in E.W. Scripps, which had the most insider buying activity, indicating a positive outlook for the company's performance.
Institutional Support: Institutions are also actively buying stocks, owning nearly 70% of E.W. Scripps, which provides a solid support base, while analysts remain cautious with mixed ratings and sentiment.
Market Sentiment and Analyst Ratings: Despite increased coverage and a generally firm sentiment, analysts have mixed reviews, with some rating stocks as a hold, while others see potential upside, particularly in sectors like service property trusts.
Catalysts for Growth: Key catalysts for growth in various stocks include international expansion, improvements in cash flow, and advancements in technology, which could enhance performance as the year progresses.
See More
Loar Holdings and Korro Bio Insider Trading Updates
- Charles Dirkson Purchase: On Thursday, Charles R. Dirkson bought 44,000 shares of LOAR at $67.45 each, totaling an investment of $2.97 million, indicating strong confidence in the company's future.
- Market Reaction: Despite Dirkson's purchase price of $67.45, LOAR shares are currently trading at $62.98, which is 6.6% below his purchase price, reflecting short-term market volatility.
- Korro Bio Insider Buying: Rick Yang purchased 207,100 shares of Korro Bio on Tuesday at $11.11 each, totaling an investment of $2.30 million, signaling optimism about the company's prospects.
- Stock Performance: Korro Bio is up 11.1% on Friday, with shares reaching a high of $14.79 during trading, resulting in a 33.1% return on Yang's investment at the peak of the trading session.
See More
Korro Bio Stock Rises on Earnings Beat and Analyst Upgrades
- Earnings Beat: Korro Bio's latest earnings report reveals significant revenue growth, driving stock price appreciation and reflecting strong performance and market confidence in the biopharmaceutical sector.
- Analyst Upgrades: Several analysts have upgraded their outlook on Korro Bio, citing the substantial market potential of its new drug candidate, which enhances investor expectations for the company's future growth.
- New Drug Candidate Highlight: The newly introduced drug candidate is considered to have breakthrough advancements in treating specific diseases, with potential positive outcomes in upcoming clinical trials, further boosting stock performance.
- Long-Term Growth Strategy: Korro Bio plans to increase R&D investments, focusing on the development of innovative drugs, aiming for sustainable long-term growth through continuous technological advancements and market expansion.
See More
KORRO BIO INC: RAYMOND JAMES UPGRADES TO OUTPERFORM FROM MARKET PERFORM
Raymond James Raises Outlook: The financial services firm Raymond James has increased its performance outlook based on recent market trends.
Market Performance Insights: The adjustments in outlook reflect a positive assessment of market conditions and potential growth opportunities.
See More
Korro Bio Reports FY Loss, Revenue Surges 181.9%
- Earnings Miss: Korro Bio reported a FY GAAP EPS of -$12.48, missing expectations by $3.43, indicating challenges in profitability that could dampen investor confidence.
- Revenue Surge: The company achieved revenue of $6.4M, a remarkable 181.9% year-over-year increase, exceeding market expectations by $1M, suggesting strong market acceptance of its products or services and laying a foundation for future growth.
- Successful Fundraising: Korro announced an oversubscribed $85 million private placement, reflecting investor confidence in its future prospects, with funds earmarked for accelerating R&D and market expansion.
- Market Engagement: Korro Bio presented at the J.P. Morgan Healthcare Conference, garnering attention from analysts and investors, which may lead to increased collaboration opportunities and market exposure.
See More
Korro Bio Showcases RNA Editing Technology at Multiple International Conferences
- Conference Presentations: Korro Bio will present its GalNAc-conjugated oligonucleotide KRRO-121 at the 3rd International Conference on Ureagenesis Defects from April 22-24, 2026, showcasing its robust ammonia clearance in preclinical hyperammonemia models, highlighting its potential in treating rare diseases.
- ASGCT Participation: At the American Society of Gene and Cell Therapy Annual Meeting from May 11-15, 2026, Korro will discuss the effectiveness of its RNA editing oligonucleotide in restoring Alpha-1 Antitrypsin function in AATD models, demonstrating its application prospects in precision medicine.
- Technological Innovations: Korro's OPERA® platform will be featured at the TIDES USA conference from May 11-14, 2026, emphasizing its innovations in large-scale RNA editing that are crucial for generating drug candidates, potentially accelerating the development of new therapies.
- EASL Congress Involvement: At the EASL Congress from May 27-30, 2026, Korro will present research on the increased healthcare resource utilization associated with uncontrolled ammonia in hepatic encephalopathy, further underscoring its contributions to liver disease research.
See More
"Q1's 5 Major Insider Purchases: Should You Buy, Sell, or Hold in Q2?"
Insider Buying Trends: In Q1 2026, insiders showed strong confidence by purchasing stocks, particularly in E.W. Scripps, which had the most insider buying activity, indicating a positive outlook for the company's performance.
Institutional Support: Institutions are also actively buying stocks, owning nearly 70% of E.W. Scripps, which provides a solid support base, while analysts remain cautious with mixed ratings and sentiment.
Market Sentiment and Analyst Ratings: Despite increased coverage and a generally firm sentiment, analysts have mixed reviews, with some rating stocks as a hold, while others see potential upside, particularly in sectors like service property trusts.
Catalysts for Growth: Key catalysts for growth in various stocks include international expansion, improvements in cash flow, and advancements in technology, which could enhance performance as the year progresses.
See More
Loar Holdings and Korro Bio Insider Trading Updates
- Charles Dirkson Purchase: On Thursday, Charles R. Dirkson bought 44,000 shares of LOAR at $67.45 each, totaling an investment of $2.97 million, indicating strong confidence in the company's future.
- Market Reaction: Despite Dirkson's purchase price of $67.45, LOAR shares are currently trading at $62.98, which is 6.6% below his purchase price, reflecting short-term market volatility.
- Korro Bio Insider Buying: Rick Yang purchased 207,100 shares of Korro Bio on Tuesday at $11.11 each, totaling an investment of $2.30 million, signaling optimism about the company's prospects.
- Stock Performance: Korro Bio is up 11.1% on Friday, with shares reaching a high of $14.79 during trading, resulting in a 33.1% return on Yang's investment at the peak of the trading session.
See More
Korro Bio Stock Rises on Earnings Beat and Analyst Upgrades
- Earnings Beat: Korro Bio's latest earnings report reveals significant revenue growth, driving stock price appreciation and reflecting strong performance and market confidence in the biopharmaceutical sector.
- Analyst Upgrades: Several analysts have upgraded their outlook on Korro Bio, citing the substantial market potential of its new drug candidate, which enhances investor expectations for the company's future growth.
- New Drug Candidate Highlight: The newly introduced drug candidate is considered to have breakthrough advancements in treating specific diseases, with potential positive outcomes in upcoming clinical trials, further boosting stock performance.
- Long-Term Growth Strategy: Korro Bio plans to increase R&D investments, focusing on the development of innovative drugs, aiming for sustainable long-term growth through continuous technological advancements and market expansion.
See More
KORRO BIO INC: RAYMOND JAMES UPGRADES TO OUTPERFORM FROM MARKET PERFORM
Raymond James Raises Outlook: The financial services firm Raymond James has increased its performance outlook based on recent market trends.
Market Performance Insights: The adjustments in outlook reflect a positive assessment of market conditions and potential growth opportunities.
See More
Korro Bio Reports FY Loss, Revenue Surges 181.9%
- Earnings Miss: Korro Bio reported a FY GAAP EPS of -$12.48, missing expectations by $3.43, indicating challenges in profitability that could dampen investor confidence.
- Revenue Surge: The company achieved revenue of $6.4M, a remarkable 181.9% year-over-year increase, exceeding market expectations by $1M, suggesting strong market acceptance of its products or services and laying a foundation for future growth.
- Successful Fundraising: Korro announced an oversubscribed $85 million private placement, reflecting investor confidence in its future prospects, with funds earmarked for accelerating R&D and market expansion.
- Market Engagement: Korro Bio presented at the J.P. Morgan Healthcare Conference, garnering attention from analysts and investors, which may lead to increased collaboration opportunities and market exposure.
See More
